期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

泌乳素腺瘤耐溴隐亭治疗的研究进展 被引量：8

原文传递
导出
摘要 泌乳素腺瘤是最常见的垂体功能性腺瘤，约占所有垂体功能性腺瘤的40％-60％。20世纪80年代以前，泌乳素腺瘤一直采用手术和放射治疗；而多巴胺受体激动剂（Dopaminergic Agonist，DA）的出现使泌乳素腺瘤的治疗发生了根本性改变，其代表性药物为溴隐亭（Bromocriptine．BRC）。
作者 苏志鹏 吴哲褒 于春江
机构地区 温州医学院附属第一医院神经外科 北京三博复兴脑科医院
出处 《中华神经外科杂志》 CSCD 北大核心 2006年第6期386-387,共2页 Chinese Journal of Neurosurgery
关键词 泌乳素腺瘤 放射治疗 溴隐亭 多巴胺受体激动剂 功能性腺瘤 20世纪 垂体
分类号 R736.4 [医药卫生—肿瘤] R736.405 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1吴哲褒,于春江.溴隐亭治疗侵袭性巨大泌乳素腺瘤的长期随访结果[J].中华神经外科杂志,2005,21(3):131-137. 被引量：31
  • 2Molitch ME. Dopamine resistance of prolactinomas. Pituitary, 2003,6 : 19-27.
  • 3于春江,吴哲褒.侵袭性巨大泌乳素腺瘤的综合治疗(附30例报告)[J].中华神经外科杂志,2004,20(2):136-140. 被引量：16
  • 4Pellegrini I, Costa R, Grisoli F, et al. Abnormal dopamine sensitivity in some human prolactinomas. Horm Res, 1989, 31 : 19-23.
  • 5Morange I, Barlier A, Pellegrini I, et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagoline and outcome of pregnancy. Eur J Endocrinol, 1997, 135: 413-420.
  • 6Sarno AD, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromoefiptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab, 2001,86: 5256-5261.
  • 7Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res,1998, 49 : 250-253.
  • 8Popadic A, Witzmann A, Buchfelder M, et al. Malignant prolactinoma case report and review of the literature. Surg Neurol,1999, 51 : 47-55.
  • 9Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine resistant prolactinomas. Neuroendocrinol, 1994, 60: 314-322.
  • 10Missale C, Losa M, Sigala S, et al. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol, 1996, 10 : 272-285.

二级参考文献76

  • 1Molitch ME. Medical treatment of prolactinomas.Endocrinol Metab Clin North Am, 1999, 28(1):143-169.
  • 2Brown ER, Coker GT, O' Malley KL. Organization and evolution of the rat tyrosine hydroxylase gene. Biochemistry,1987, 26(16):5208-5212.
  • 3Freese A, During M J, Davidson BL, et al. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release.J Clin Endocrinol Metab, 1996, 81(6):2401-2404.
  • 4He TC, Zhou SB, Costar LTD, et al. A simplified system for generating recombinant adenovirus. Proc Nail Acad Sci USA, 1998, 95(5):2509-2514.
  • 5Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med, 1998, 30(5):452-459.
  • 6Tyrrell JB, Lambom KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgey, 1999, 44(2):254-263.
  • 7During M J, Naegele JR, O' Malley KL, et al. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science, 1994, 266(25):1399-1403.
  • 8Moffat M, Harmon S, Haycock J, et al. L-dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease. Exp Neurol, 1997, 144(1):69-73.
  • 9Windeatt S, Southgate TD, Dewey RA, et al. Adenovirusmediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.J Clin Endocrinol Metab, 2000, 85(3):1296-1305.
  • 10Neill JD, Musgrove LC, Duck LW, et al. High efficiency method for gene transfer in normal pituitary gonadotropes:adenoviral-mediated expression of G protein-coupled receptor kinase 2 suppresses luteinizing hormone secretion. Endocrinology, 1999, 140(6):2562-2569.

共引文献55

同被引文献126

引证文献8

二级引证文献48

中华神经外科杂志
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部